London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So we need Blue Cap approval to launch in China, similar to EFSA over here. Anyone know what the agenda is? Can't find info re MOU firming to a firm deal. A load of Q's to answer! The IP looks undervalued though if we can take a guess on that in relation to market cap.
Made a start over last session, I don't wear it that a safe product which can help millions of Chinese to survive pollution, supports elite Olympic level athletes, extends the lives (probably) for hundreds of millions re platelet aggregation leading to thrombosis! blood pressure reduction re Uni of Oslo which is a World Class institution.
I'll go for the main point that the IP is valuable, start with that and work through the rest.
sphinx 100:- you quote true facts about the long term alliance between DSM and Provexis and highlights to me that something very big is in the pipe line:- (note Dr.Niamh, our research chemist, appointed to board with immediate effect has been working for Provexis since the year 2000.. Note;- " Strategy, co-ordination, organisation and implementation will be governed by an Alliance Board with representatives from both companies." "The agreement is based on a long-term cooperation between the partners." Note>- "The Alliance will give DSM exclusive global rights to Fruitflow and will see the partners collaborate to develop Fruitflow® in all major global markets, through an effective commercialisation of current formats and pioneering new and significant applications. Strategy, co-ordination, organisation and implementation will be governed by an Alliance Board with representatives from both companies. The agreement is based on a long-term cooperation between the partners." And the last RNS on the 12th April 2019:- (stating with immediate effect) and thats on top of DSM's executive Director with all his global contacts just recently appointed to Provexis board, clearly shows to me that some thing very big is in the Pipe Line as Dr Niamh O'Kennedy who has been working with Provexis since the year 2000 has now been appointed as an executive director representing Provexis in the partnership.. (some thing big in the pipe line in my opinion,) something to do with the collaboration deal between Provexis and DSM and the Chinese company By-Health who is further researching the many benefits of Fruitflow at its own cost. . IMHO All looking good and the last time a collaboration deal was going on between Provexis and Co ca Cola the share price shot up from 0.6p to 15p in less then a yea until the deal fell through..
"Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven FruitflowÂ® heart-health functional food ingredient, is pleased to announce the appointment of Dr Niamh O'Kennedy an Executive Director of the Company, and as Chief Scientific Officer, with immediate effect."
"Niamh is a research chemist, specialising in the field of natural products chemistry, who has been working with Provexis since 2000. Niamh's experience in isolating and characterising plant-derived compounds and understanding the roles these play in complex biological systems has been pivotal in the development of Provexis' lead product, FruitflowÂ®, and the health claim for FruitflowÂ® which was adopted by the European Food Safety Authority ('EFSA')."
BB had a read of the 2010 results and found this interesting , “Initially the Company, supported by IFR’s substantial research, will focus on developing commercial products targeting the reduction of cardiovascular inflammation. A longer-term objective is to develop technologies designed to mitigate the risk of certain major cancers.” I wonder what happened with that research !
The AA was put in place for a 12 year period, so is due to run out some time in 2022 ( probably June if it's exactly 12 years ). I don't have the link to hand, but it was in an RNS once ( only once though if memory serves me right )
The Alliance will give DSM exclusive global rights to Fruitflow andwill see the partners collaborate to develop Fruitflow® in all major global markets, through an effective commercialisation of current formats and pioneering new and significant applications. Strategy, co-ordination, organisation and implementation will be governed by an Alliance Board with representatives from both companies. The agreement is based on a long-term cooperation between the partners.
DSM will be responsible for: manufacturing; marketing; and selling via its global sales force. Provexis will be responsible for contributing scientific expertise necessary for successful commercialisation.
Profits from the Alliance will be shared by the parties on an agreed basis, linked to various performance milestones. All other commercial terms of the Alliance remain confidential between the two parties.
Does anyone know what pxs could potentially be worth? I appreciate that this would usually be calculated on sales and profits which at the moment fail to cover costs. However, what might a take over look like? What is the IP worth to a company like DSM, by health etc? Does anyone have any knowledge or experience of similar companies, products, IP etc that have come good and to what extent? Thanks.
Fair point. One of the issues causing less buying is the lack of transparency in both the sales of all the Fruitflow products on the market, and the details of the profit share agreement signed in 2010. It was pointed out to me in a discussion that the agreement hasn't got that much longer to run. As you rightly say, that's another thing that could be viewed positively or negatively. The tiresome part is the compulsion P/C feels to retort with an unanswerable point.
Meaning? As far as I can see, what Nigel has written is factual. The Chinese collaboration to further research and develop Fruitflow is yet to be signed, but they've already had a year's worth of studies funded solely by themselves. All of which is stating the bleedin obvious of course. Pumpky/Cinders can't help having a dig no matter what, knowing full well that the terms of the Alliance Agreement remain confidential. Tiresome and unnecessary IMO